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Abstract: This Article presents further examples of the 
enantioselective rhodium-catalyzed addition of potassium 
allyltrifluoroborates to cyclic imines. A wide range of substituted 
allyltrifluoroborates are compatible with this process, and provide 
protected homoallylic amines with high levels of diastereo- and 
enantioselection. The reactions display a strong preference for 
carbon‒carbon bond formation at the more substituted terminus of 
the allyl fragment of the allyltrifluoroborate, regardless of the 
position of the boron atom. Representative examples of 
manipulation of the products are also described. 
Key words: allyltrifluoroborates, asymmetric catalysis, 
enantioselectivity, imines, rhodium 
 
Introduction

 
 
The enantioselective rhodium(I)-catalyzed addition of 
organoboron reagents to -electrophiles is now a well-
established method for the synthesis of enantioenriched 
chiral compounds.
1
 The stability, functional group 
tolerance, and usually low toxicity of organoboron 
compounds, coupled with the ability of a broad range of 
chiral ligands to impart high levels of enantioselection 
across several classes of reactions, has resulted in this 
method being widely applied in synthesis. Thus far, 
efforts have focused mainly upon nucleophilic 
arylations
1
 and alkenylations
2
 using the corresponding 
organoboron reagents, though one example of the use of 
alkynylboron reagents
3
 has also been described.
4,5 
Although catalytic enantioselective nucleophilic 
allylations occupy a prominent position in organic 
synthesis,
6,7
 it was not until our recent investigation
8
 that 
an enantioselective rhodium-catalyzed allylboration
9,10
 
was achieved. Prompted by the general utility of chiral 
homoallylic amines in synthesis,
6b,11,12
 along with the 
increasing body of work describing the catalytic 
enantioselective allylborations of imines,
11
 we 
developed
8
 the enantioselective addition of potassium 
allyltrifluoroborates to cyclic imines,
13
 catalyzed by a 
rhodium complex based upon the chiral diene L1
14,15
 
(Scheme 1A). In this study, the reactions using 
substituted allyltrifluoroborates displayed two notable 
features. First, clean allylic transposition was observed,  
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Scheme 1  Previously reported rhodium(I) catalyzed allylation of 
cyclic imines. 
resulting in C‒C bond formation at the γ-carbon of the 
allyltrifluoroborate. Second, high levels of 
stereochemical transfer were observed. For example, the 
reactions of aldimine 1 with (E)- and (Z)-
crotyltrifluoroborates 2a and 2b proceeded with different 
stereochemical outcomes to provide diastereomeric 
products 3a and 3b, respectively, with high diastereo- 
and enantioselectivities (Scheme 1B).
8
 A cyclic chairlike 
transition state TS1 was invoked to rationalize the 
stereochemical outcomes. 
This Article presents further examples of this process, 
using classes of imines and substituted 
allyltrifluoroborates additional to those described in our 
original study.
8 
As well as providing a more thorough 
understanding of the substrate scope, some of the results 
using allyltrifluoroborates reveal cases of α-selectivity in 
the reactions, which we have not observed previously. 
Finally, representative examples of manipulations of the 
allylation products are presented. 
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Further Evaluation of Substrate Scope 
 
In our original investigation, four distinct classes of 
cyclic imines were shown to undergo enantioselective 
allylation. These were benzoxathiazine-2,2-dioxides, 
1,2,6-thiadiazine-1,1-dioxides, 1,2,5-thiadiazolidine-1,1-
dioxides, and cyclic sulfamidates.
8
 We have since found 
that other cyclic N-sulfonyl ketimines 4a‒4c are also 
effective substrates (Scheme 2). For example, using the 
rhodium complex derived from ent-L1
14
 (the enantiomer 
of the chiral diene employed in our original study
8
), 
methyl- and n-butyl-substituted ketimines underwent 
allylation with potassium allyltrifluoroborate (2c) under 
our established conditions
8
 to give benzosultams 5a and 
5b, respectively, in moderate yields but with high 
enantioselectivities. It appears that the allylations of 
imines containing electron-withdrawing substituents 
proceed with lower enantioselectivities. For example, a 
substrate 4c containing an ethyl ester underwent 
allylation in only 21% ee (product 5c). In addition, 
ketimine 6 containing a trifluoromethyl group underwent 
allylation in 85% yield but the product 7 was racemic 
(Scheme 3). In our previous study, benzoxathiazine-2,2-
dioxides containing electron-withdrawing substituents on 
the benzene ring were also allylated in lower 
enantioselectivities under our standard conditions using 
MeOH (5 equiv) in THF/dioxane, but fortunately the use 
of i-PrOH (13 equiv) in toluene/dioxane gave better 
 
 
Biographical Sketches  
 
 
Hamish B. Hepburn was 
born in 1988 in Dundee, 
Scotland. He completed a 
master’s degree in chemistry 
at the University of 
Edinburgh in 2011, which 
included a one year 
placement at AstraZeneca. 
He is currently conducting 
Ph.D. studies in the group of 
Dr. Hon Wai Lam at the 
University of Edinburgh, 
investigating rhodium-
catalyzed enantioselective 
transformations. 
 
 
 
 
Nawasit Chotsaeng was 
born in 1982 in Roi Et, 
Thailand. After attaining a 
bachelor’s degree at King 
Mongkut’s Institute of 
Technology Ladkrabang in 
2005, he completed a 
master’s degree at the same 
institution in 2009. He is 
currently conducting Ph.D. 
research on new transition-
metal-catalyzed reactions in 
the group of Dr. Hon Wai 
Lam at the University of 
Edinburgh, funded by a 
Royal Thai Government 
Scholarship. 
 
Yunfei Luo was born in 
1975 in Yunnan Province, 
China. He received a 
bachelor’s degree in 
chemistry from Fudan 
University in 1998 and a 
master’s degree from the 
same institution in 2001. He 
was a research associate at 
the Shanghai Institute of 
Organic Chemistry between 
2001 and 2004, and worked 
in industry between 2004 
and 2006. He obtained a 
Ph.D. degree in 2010 under 
the supervision of Dr. 
Andrew Carnell at the 
University of Liverpool, and 
is currently undertaking 
postdoctoral research in the 
group of Dr. Hon Wai Lam 
at the University of 
Edinburgh, focusing on 
asymmetric catalysis. 
 
 
 
 
Hon Wai Lam was born in 
1976 in Harrow, England. 
He received an M.Chem. 
degree in chemistry from the 
University of Oxford in 
1998. He then moved to the 
University of Nottingham to 
carry out his Ph.D. under the 
direction of Gerald 
Pattenden. In January 2002, 
he moved to Harvard 
University as a GSK 
Postdoctoral Fellow to work 
with David A. Evans. In 
October 2003, he joined the 
School of Chemistry at the 
University of Edinburgh 
where he is now a Reader in 
Organic Chemistry. In 
October 2013, Hon will take 
up a new appointment at the 
University of Nottingham as 
the GSK Chair of 
Sustainable Chemistry. His 
group’s research interests are 
based around the 
development of new 
synthetic methodology, 
including enantioselective 
catalysis and C‒H 
functionalization chemistry. 
3  FEATURE ARTICLE  
Template for SYNLETT and SYNTHESIS © Thieme  Stuttgart · New York 2013-07-23 page 3 of 14 
 
Scheme 2  Enantioselective allylation of imines 4a‒4c. 
 
Scheme 3 Allylation of imine 6. 
results.
8
 However, application of these modified 
conditions to the synthesis of products 5c and 7 did not 
offer any improvement in enantioselection. 
Table 1 presents the reactions of cyclic ketimine 4a with 
a range of substituted potassium allyltrifluoroborates.
16
 
Consistent with our previous report,
8
 the β-n-propyl-
substituted allyltrifluoroborate 2d was an effective 
allylating agent, and reacted with 4a to provide 8a in 
high diastereo- and enantioselectivity, though in a 
modest yield (entry 1). Allyltrifluoroborates not reported 
in our original investigation were also effective. For 
example, the γ-phenyl-substituted allyltrifluoroborate 2e 
gave 8b in 86% yield as one observable diastereomer in 
91% ee (entry 2), while β-methylallyltrifluoroborate 2f 
provided 8c in 56% yield and 98% ee (entry 3).  
Up until this point, all of the reactions that we have 
studied that involve substituted allyltrifluoroborates have 
employed reagents in which boron is bonded to a 
primary carbon atom. In these cases, C‒C bond 
formation occurred exclusively at the γ-carbon of the 
allyltrifluoroborate. It was therefore of interest to 
examine the reactions using racemic α-methyl-
substituted allyltrifluoroborate 2g, where boron is 
bonded to a secondary carbon atom. On the basis of an 
experiment using a deuterated potassium 
allyltrifluoroborate, we speculate that these allylations 
proceed via the intermediacy of allylrhodium species.
8
 
According to this hypothesis, transmetallation of rac-2g 
with the chiral rhodium complex could therefore, in 
principle, lead to several interconverting isomeric 
Table 1 Enantioselective Allylation of Imine 4a with Substituted 
Potassium Allyltrifluoroborates.
a 
 
Entry Allyltrifluoroborate Product Yield (%)
b
 dr
c 
ee (%)
d 
1 
 
 
48 >19:1 98 
 2d 8a      
2 
  
86 >19:1 91 
 2e 8b    
3 
  
56 ‒ 98 
 2f 8c      
a Reactions were conducted using 0.30 mmol of 4a. b Isolated yield. c 
Determined by 1H NMR analysis of the unpurified reaction mixtures. d 
Determined by chiral HPLC analysis. 
  
Scheme 4  Possible outcomes of reactions using α-methyl-substituted 
allyltrifluoroborate 2g. 
 
allylrhodium species, each of which would provide 
different products upon reaction with imine 4a (Scheme 
4). As such, it was not clear whether the γ-selectivity 
observed previously
8
 would be maintained using rac-2g. 
In the event, allylation of 4a with rac-2g provided a 
mixture of diastereomeric products 8d and 11 with high 
enantioselectivities, where C‒C bond formation occurred 
at the α-carbon of rac-2g (Scheme 5).
16
 Other isomeric 
products such as 8e were not observed. In addition to  
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Scheme 5  Reaction of imine 4a with the α-methyl-substituted 
allyltrifluoroborate 2g. 
providing further evidence that these allylations proceed 
via allylrhodium intermediates, this result indicates that  
the contributions to the observed products are greatest 
for crotylrhodium species (E)-9, followed by (Z)-9, 
while the contribution of 10 is negligible. If the 
interconversion between the different allylrhodium 
species is rapid compared with the rates of imine 
allylation, the product ratio will depend only upon the 
relative rates of allylation from (E)-9, 10, and (Z)-9, and 
not upon their equilibrium distribution (Curtin‒
Hammett-type kinetics
17
). However, the high degrees of 
stereochemical transfer observed in the allylations of 
imine 1 using (E)- and (Z)-crotyltrifluoroborates 2a and 
2b (see Scheme 1B) suggests that isomerization between 
(E)-9 and (Z)-9 is slow compared with the rate of 
allylation. Therefore, if a similar scenario is operative in 
the allylation of imine 4a with rac-2g, it is likely that the 
ratio of 8d and 11 obtained depends significantly on the 
ratio of (E)-9 and (Z)-9 formed in the initial 
transmetallation. 
Next, the allylations of aldimine 1 and ketimine 12 with 
a range of substituted allyltrifluoroborates not reported 
in our original study
8
 were conducted, and these 
reactions generally proceeded with high diastereo- and 
enantioselectivities (Table 2).
16 
In certain cases, the use 
of i-PrOH (5 equiv) in toluene/dioxane provided higher 
enantioselectivities compared with our standard 
conditions of MeOH (5 equiv) in THF/dioxane (products 
13a, 13b, and 13d). Consistent with the result shown in 
Table 1, entry 2, 2e was a highly effective allylating 
agent, and reacted with imines 1 and 12 to give 13a and 
13e, respectively, in good yields and high 
stereoselectivities. Although β-methyl substituted 
allyltrifluoroborate 2f reacted with ketimine 12 to give 
13f in good yield and high enantioselectivity, the ee was 
lower in the reaction with aldimine 1 (13b obtained in 
79% ee). As an example of an allyltrifluoroborate 
containing substitution at both the α- and γ-carbons, 
cyclohexenyltrifluoroborate 2h was evaluated. This 
reagent was only moderately effective, as the reaction 
with aldimine 1 provided 13c in only 36% yield, though 
with good diastereo- and enantioselectivity.
16
 The 
reaction of 2h with ketimine 12 was completely  
Table 2 Reaction of Imines 1 and 12 with Substituted 
Allyltrifluoroborates.
a
 
 
Allyltrifluoroborate Product using 1 Product using 12 
   
2e 13a  90%
b 
19:1 dr, 95% ee 
13e  86%
 
19:1 dr, 95% ee 
   
2f 13b  65%
b
 
79% ee 
13f  90% 
97% ee 
   
2h 13c  36% 
10:1 dr, 93% ee 
13g  <5% 
   
2i 13d  71%
b 
90% ee 
13h  87% 
91% ee 
a Reactions were conducted using 0.30 mmol of 1 or 12. Cited yields are of 
isolated products. Diastereomeric ratios were determined by 1H NMR 
analysis of the unpurified reaction mixtures. Enantiomeric excesses were 
determined by chiral HPLC analysis. b Reaction conducted using i-PrOH 
(5 equiv) in toluene/dioxane instead of MeOH in THF/dioxane. 
 
unsuccessful, and provided a complex mixture of 
unidentified products. The α,α-dimethyl- substituted 
allyltrifluoroborate 2i resulted in C‒C bond formation at 
the α-carbon exclusively, and provided reverse 
prenylation products 13d and 13h with good yields and 
high enantiomeric excesses. Interestingly, our previous 
study demonstrated that prenyltrifluoroborate 2j, the 
isomer of 2i, resulted in the formation of the enantiomers 
of 13d and 13h when L1 was used (Scheme 6).
8
 The 
formation of the reverse prenylation products 13d and 
13h from both allyltrifluoroborates 2i (α-selectivity) and 
2j (γ-selectivity) suggests that allylation proceeds via 
allylrhodium species 15 rather than the isomeric species 
14 (Scheme 7). 
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Scheme 6  Allylation of imines 1 and 12 with prenyltrifluoroborate 2j. 
 
Scheme 7  Allylrhodium species from allyltrifluoroborates 2i and 2j. 
 
The reactions of imines 1 and 12 with α-methyl-
substituted allyltrifluoroborate 2g proceeded with similar 
outcomes to the corresponding reaction with imine 4a 
(Schemes 8 and 9, compare with Scheme 5). In the case 
of imine 1, two products ent-3a and ent-3b were 
produced as an inseparable 2.3:1 mixture in 60% 
combined yield, and with enantiomeric excesses of 93% 
ee and 97% ee, respectively (Scheme 8). With imine 12, 
the two products 13i and 13j were separable, and were 
isolated in 48% and 16% yields, respectively, and in high 
enantioselectivities (Scheme 9). 
 
 
Scheme 8  Reaction of imine 1 with the α-methyl-substituted 
allyltrifluoroborate 2g.  
 
 
Scheme 9  Reaction of imine 12 with the α-methyl-substituted 
allyltrifluoroborate 2g.  
Functionalizations of the Allylation Products 
 
To demonstrate the utility of the allylation products, 
representative transformations were conducted. For 
example, removal of the sulfonyl group of 16 (obtained 
in our original investigation using ligand L1
8
) was 
readily accomplished by treatment with LiAlH4; in situ 
reaction of the resulting amine with Boc2O then provided 
carbamate 17 in 85% overall yield (Scheme 10). 
 
 
Scheme 10 Removal of the sulfonyl group of 16. 
A hydroboration/oxidation sequence of the alkene of ent-
16 (prepared as described previously
8
 by the reaction of 
imine 1 with potassium allyltrifluoroborate, but using 
chiral diene ent-L1) provided primary alcohol 18, which 
was transformed into the tricyclic sulfamate 19 by a 
Mitsunobu cyclization (Scheme 11). 
 
 
Scheme 11  Conversion of ent-16 into tricyclic sulfamate 19.  
Alternatively, treatment of 18 with LiAlH4 followed by 
Boc2O provided carbamate 20, which was converted into 
the tetrahydrobenzoxepine 21 by a Mitsunobu 
cyclization. Amino-substituted tetrahydrobenzoxepines 
have been shown to exhibit interesting biological  
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Scheme 12  Conversion of 18 into amino-substituted 
tetrahydrobenzoxepine 22.  
 
activities; compound 22, for example, is a strong ACAT 
(acyl coenzyme A, cholesterol O-acyltransferase) 
inhibitor.
18
 
Finally, the imine of the allylation product 23 (prepared 
as described previously
8
 by the reaction of imine 12 with 
potassium allyltrifluoroborate, but using chiral diene ent-
L1) underwent a highly diastereoselective reduction 
upon treatment with DIBAL at ‒20 °C to give 24 in 90% 
yield as a single observable diastereomer (Scheme 13).
19
 
Heating 24 in dioxane in the presence of ethylene 
diamine (10 equiv) removed the sulfonyl group to 
provide 1,2-diamine 25 in 88% yield. 
 
 
Scheme 13  Conversion of 23 into 1,2-diamine 25 
Conclusion 
In summary, the reactions described herein, using imines 
and potassium allyltrifluoroborates additional to those 
described in our original study,
8
 further illustrate the 
scope of the enantioselective rhodium-catalyzed 
allylboration of cyclic imines. In particular, these studies 
highlight the strong preference for C‒C bond formation 
to occur at the more highly substituted end of the allyl 
fragment of the trifluoroborate, regardless of the position 
of the boron atom (e.g. compare Schemes 5, 8, and 9, 
along with products 13d and 13h in Table 2 with 
Schemes 1B and 6). Finally, the utility of the allylation 
products was demonstrated by representative 
transformations. 
All commercially available reagents were used as received. 
Anhydrous dioxane was purchased from Sigma-Aldrich and used 
without further purification. Anhydrous THF, toluene, and CH2Cl2 
were obtained by passage through activated alumina columns 
using a solvent purification system.  Flash column 
chromatography was carried out using silica gel (Fisher Scientific 
60Å particle size 35-70 micron). Melting points were recorded on 
a Gallenkamp melting point apparatus and are uncorrected. IR 
spectra were recorded on a Shimadzu IRAffinity-1 instrument. 1H 
NMR spectra were recorded on a Bruker AVA500 (500 MHz) or a 
Bruker AVA400 (400 MHz) spectrometer. Chemical shifts (δ) are 
quoted in parts per million (ppm) downfield of tetramethylsilane, 
using residual protonated solvent as internal standard (CDCl3 at 
7.27 ppm, CD3CN at 1.94 ppm, CD3OD at 3.31 ppm). 
Abbreviations used in the description of resonances are: s 
(singlet), d (doublet), t (triplet), q, (quartet), app (apparent), br 
(broad), m (multiplet). Coupling constants (J) are quoted to the 
nearest 0.1 Hz. Proton-decoupled 13C NMR spectra were recorded 
on a Bruker AVA500 (125.8 MHz) spectrometer. Chemical shifts 
(δ) are quoted in parts per million (ppm) downfield of 
tetramethylsilane, using deuterated solvent as internal standard 
(CDCl3 at 77.0 ppm, CD3CN at 118.26 ppm, CD3OD at 49.0 
ppm). Assignments were made using the DEPT sequence with 
secondary pulses at 90° and 135°. Proton-decoupled 19F NMR 
spectra were recorded on a Bruker AVA400 (376 MHz) 
spectrometer. Chemical shifts (δ) are quoted in parts per million 
(ppm) downfield of CFCl3, using residual protonated solvent as 
internal standard (CFCl3 at 376.38 MHz with respect to 
tetramethylsilane at 400.00 MHz). High-resolution mass spectra 
were recorded using electrospray ionization (ESI): or electron 
impact (EI): techniques on a Finnigan MAT 900 XLT 
spectrometer. Optical rotations were performed on an Optical 
Activity POLAAR 20 polarimeter. Chiral HPLC analysis was 
performed on an Agilent 1100 instrument using 4.6 x 250 mm 
columns. Authentic racemic samples of products for chiral HPLC 
assay determinations were obtained using [Rh(cod)Cl]2 (2.5 
mol%) as an achiral precatalyst. Chiral diene ent-1 was prepared 
as described previously.14 Imines 1,8 4a,20 4b,21 4c,13c 6,22 and 1223 
were prepared according to previously described procedures. 
Potassium allyltrifluoroborates 2c24 and 2d8 were prepared as 
described previously.  
 
Preparation of Potassium Allyltrifluoroborates: General 
Procedure A 
Following a slight modification of the procedure of Lennox and 
Lloyd-Jones,25 to a solution of the appropriate allylboronic acid 
pinacol ester (1.0 equiv) in MeOH (2 mL/mmol) and MeCN (2 
mL/mmol) at room temperature was added a solution of KF (4.0 
equiv) in H2O (0.1 mL/mmol), and the mixture was stirred for 5 
min until complete dissolution occurred. To this solution was 
added a solution of L-(+)-tartaric acid (2.05 equiv) in THF (1.5 
mL/mmol of allylboronic acid pinacol ester) dropwise, and the 
resulting mixture was stirred at room temperature for 1 h. MeCN 
(5 mL/mmol of allylboronic acid pinacol ester) was added and the 
reaction was stirred for an additional 5 min before being filtered 
and concentrated in vacuo to leave a mixture of the potassium 
allyltrifluoroborate and pinacol. This residue was heated under 
reduced pressure to remove pinacol to leave the potassium 
allyltrifluoroborate as a white solid. 
 
Potassium (E)-3-phenylprop-2-en-1-yltrifluoroborate (2e)26 
The title compound was prepared according to General Procedure 
A from the corresponding allylboronic acid pinacol ester27 (488 
mg, 2.00 mmol), KF (0.46 g, 8.00 mmol), and L-(+)-tartaric acid 
(0.62 g, 4.13 mmol) to give a white solid (327 mg, 73%) that 
displayed spectroscopic data consistent with those reported 
previously.26 
 
Potassium 2-methallyltrifluoroborate (2f)  
The title compound was prepared according to General Procedure 
A from the corresponding allylboronic acid pinacol ester28 (478 
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mg, 2.63 mmol), KF (0.61 g, 10.5 mmol), and L-(+)-tartaric acid 
(0.81 g, 5.38 mmol) to give a white solid (248 mg, 58%).  
1H NMR (400 MHz CD3CN): δ = 4.34 (s, 1 H), 4.32 (s, 1 H), 1.69 
(s, 3 H), 1.14 (br s, 2 H). 
13C NMR (100.6 MHz, CD3CN): δ = 116.5, 110.3, 25.0, the 
carbon adjacent to the boron was not observed. 
19F NMR (376 MHz, CD3CN): δ = –152.4.  
 
(±)-Potassium α-methylallyltrifluoroborate (2g) 
The title compound was prepared according to General Procedure 
A from the corresponding allylboronic acid pinacol ester28 (910 
mg, 5.00 mmol), KF (1.16 g, 20.0 mmol), and L-(+)-tartaric acid 
(1.54 g, 10.3 mmol) to give a white solid (570 mg, 70%).  
1H NMR (400 MHz, CD3CN): δ = 6.04 (ddd, J = 17.3, 10.3, 6.9 
Hz, 1 H), 4.66 (d, J = 17.3 Hz, 1 H), 4.60 (d, J = 10.3 Hz, 1 H), 
1.14 (br s, 1 H), 0.85 (d, J = 6.7 Hz, 3 H). 
13C NMR (100.6 MHz, CD3CN): δ = 110.9, 107.0, 25.1, 14.4. 
19F NMR (376 MHz, CD3CN): δ = ‒146.5. 
 
Potassium 1-cyclohex-2-enyltrifluoroborate (2h)26 
The title compound was prepared according to General Procedure 
A from the corresponding allylboronic acid pinacol ester29 (416 
mg, 2.00 mmol), KF (0.46 g, 8.00 mmol) and L-(+)-tartaric acid 
(0.62 g, 4.13 mmol) to give a white solid (290 mg, 78%) that 
displayed spectroscopic data consistent with those reported 
previously.26 
 
Potassium α,α-dimethylallyltrifluoroborate (2i) 
The title compound was prepared according to General Procedure 
A from the corresponding allylboronic acid pinacol ester28 (550 
mg, 2.80 mmol), KF (0.65 g, 11.2 mmol), and L-(+)-tartaric acid 
(0.86 g, 5.74 mmol) to give a white solid (330 mg, 67%).  
1H NMR (400 MHz, CD3CN): δ = 6.07-6.00 (m, 1 H), 4.61-4.55 
(m, 2 H), 0.79 (s, 6 H). 
13C (100.6 MHz, CD3CN): δ = 111.1, 105.1, 23.7 (2 × CH3), the 
quaternary carbon adjacent to the boron was not observed. 
19F NMR (376 MHz, CD3CN): δ = –151.3. 
 
Rh-Catalyzed Allylation of Imines: General Procedure B 
A vial containing the appropriate cyclic imine (0.30 mmol) and the 
appropriate potassium allyltrifluoroborate (0.45 mmol) was sealed 
and flushed with N2 before anhydrous THF (3 mL) was added. To 
this solution was added a stock solution of the rhodium–chiral 
diene complex [Rh(ent-L1)Cl]2 (10.0 mM in anhydrous dioxane, 
0.45 mL, 0.0045 mmol = 3 mol% Rh) followed by MeOH (60 µL, 
1.50 mmol), and the resulting mixture was heated to 55 °C for 15 
h. The reaction was cooled to room temperature, filtered through a 
short plug of silica using EtOAc as eluent, and concentrated in 
vacuo. Purification of the residue by column chromatography gave 
the allylated product. 
 
Rh-Catalyzed Allylation of Imines: General Procedure C 
A vial containing the appropriate cyclic imine (0.30 mmol) and the 
appropriate potassium allyltrifluoroborate (0.45 mmol) was sealed 
and flushed with N2 before anhydrous toluene (3 mL) was added. 
To this solution was added a stock solution of the rhodium–chiral 
diene complex [Rh(ent-L1)Cl]2 (10.0 mM in anhydrous dioxane, 
0.45 mL, 0.0045 mmol = 3 mol% Rh) followed by i-PrOH (115 
µL, 1.50 mmol), and the resulting mixture was heated to 55 °C for 
15 h. The reaction was cooled to room temperature, filtered 
through a short plug of silica using EtOAc as eluent, and 
concentrated in vacuo. Purification of the residue by column 
chromatography gave the allylated product. 
 
 
 
(S)-3-Methyl-3-(prop-2-en-1-yl)-2,3-dihydro-[1,2]-
benzothiazole-1,1-dioxide (5a)  
The title compound was prepared according to General Procedure 
B from imine 4a (54 mg, 0.30 mmol) and allyltrifluoroborate 2c 
(66 mg, 0.45 mmol) and was purified by column chromatography 
(10% EtOAc/hexane) to give a yellow oil (38 mg, 57%).  
Rf = 0.32 (30% EtOAc/hexane).  
[α] 20
D
‒54.2 (c 0.70, CHCl3).  
IR (neat): 3250 (NH), 1373, 1271, 1254, 1148, 1121, 1049, 916, 
770, 760 cm-1.  
1H NMR (500 MHz, CDCl3): δ = 7.76 (d, J = 7.8 Hz, 1 H), 7.64 
(td, J = 7.7, 1.1 Hz, 1 H), 7.53 (td, J = 7.7, 1.0 Hz, 1 H), 7.39 (d, J 
= 7.8 Hz, 1 H), 5.68 (dddd, J = 17.0, 10.3, 7.9, 6.7 Hz, 1 H), 5.24-
5.17 (m, 2 H), 4.65 (br s, 1 H), 2.71 (dd, J = 14.1, 7.1 Hz, 1 H), 
2.60 (dd, J = 14.1, 7.9 Hz, 1 H), 1.64 (s, 3 H).  
13C NMR (125.8 MHz, CDCl3): δ = 144.6, 135.7, 133.3, 131.7, 
129.2, 123.0, 121.3, 121.2, 62.9, 45.7, 27.8. 
HRMS (ESI): Exact mass calcd for C11H14NO2S [M+H]
+: 
224.0740, found: 224.0735.  
HPLC: Chiralcel OD-H column (90:10 hexane:i-PrOH, 0.8 
mL/min, 230 nm, 25 °C); tr (major) = 17.8 min, tr (minor) = 24.0 
min; 96% ee.  
 
(S)-3-Butyl-3-(prop-2-en-1-yl)-2,3-dihydro-[1,2]-benzothiazole-
1,1-dioxide (5b) 
The title compound was prepared according to General Procedure 
B from imine 4b (67 mg, 0.30 mmol) and allyltrifluoroborate 2c 
(66 mg, 0.45 mmol) and was purified by column chromatography 
(10% EtOAc/hexane) to give a yellow oil (51 mg, 64%).  
Rf = 0.45 (30% EtOAc/hexane). 
[α] 20
D
 ‒30.3 (c 1.45, CHCl3). 
IR (neat): 3281 (NH), 1466, 1375, 1271, 1153, 1132, 1034, 930, 
766, 683 cm-1.  
1H NMR (500 MHz, CDCl3): δ = 7.76 (d, J = 7.7 Hz, 1 H), 7.64 
(td, J = 7.7, 1.1 Hz, 1 H), 7.53 (td, J = 7.7, 1.0 Hz, 1 H), 7.35 (d, J 
= 7.8 Hz, 1 H), 5.63 (dddd, J = 17.1, 10.2, 7.6, 7.0 Hz, 1 H), 5.20-
5.14 (m, 2 H), 4.54 (s, 1 H), 2.70-2.60 (m, 2 H), 1.93-1.87 (m, 2 
H), 1.45-1.36 (m, 1 H), 1.32-1.23 (m, 2 H), 1.01-0.97 (m, 1 H), 
0.85 (t, J = 7.3 Hz, 3 H). 
13C NMR (125.8 MHz, CDCl3): δ = 142.9, 136.0, 133.2, 131.6, 
129.3, 123.3, 121.5, 121.1, 66.3, 45.1, 40.0, 25.7, 22.6, 13.8. 
HRMS (ESI): Exact mass calcd for C14H20NO2S [M+H]
+: 
266.1209, found: 266.1205. 
HPLC: Chiralpak AD-H column (90:10 hexane:i-PrOH, 0.8 
mL/min, 211 nm, 25 °C); tr (major) = 24.7 min, tr (minor) = 29.2 
min; 96% ee. 
 
(S)-Ethyl 5-methyl-1,1-dioxo-3-(prop-2-en-1-yl)-2,3-dihydro-
[1,2]-benzothiazole-3-carboxylate (5c) 
The title compound was prepared according to General Procedure 
B from imine 4c (76 mg, 0.30 mmol) and allyltrifluoroborate 2c 
(66 mg, 0.45 mmol) and was purified by column chromatography 
(10% EtOAc/hexane) to give a colorless oil (49 mg, 55%). 
Rf = 0.35 (30% EtOAc/hexane). 
[α] 20
D
‒22.4 (c 0.90, CHCl3). 
IR (neat): 3258 (NH), 1722 (C=O), 1261, 1231, 1182, 1144, 1134, 
1040, 702, 660 cm-1. 
1H NMR (500 MHz, CDCl3): δ = 7.63 (d, J = 8.0 Hz, 1 H), 7.51 
(s, 1 H), 7.38 (d, J = 8.0 Hz, 1 H), 5.77 (dddd, J = 16.9, 10.2, 7.8, 
6.4 Hz, 1 H), 5.69 (s, 1 H), 5.23-5.17 (m, 2 H), 4.36-4.26 (m, 2 H), 
2.96 (dd, J = 13.9, 7.8 Hz, 1 H), 2.71 (dd, J = 13.9, 6.4 Hz, 1 H), 
2.49 (s, 3 H), 1.34 (3H, t, J = 7.1 Hz, 3 H). 
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13C NMR (125.8 MHz, CDCl3): δ = 169.5, 144.6, 138.0, 132.7, 
131.4, 131.0, 125.1, 121.1, 120.7, 68.5, 63.4, 44.6, 21.8, 14.1. 
HRMS (ESI): Exact mass calcd for C14H18NO4S [M+H]
+: 
296.0951, found: 296.0951. 
HPLC: Chiralcel OD-H column (90:10 hexane:i-PrOH, 0.8 
mL/min, 211 nm, 25 °C); tr (minor) = 13.9 min, tr (major) = 18.4 
min; 21% ee. 
 
4-(Prop-2-en-1-yl)-4-(trifluoromethyl)-3,4-dihydro-[1,2,3]-
benzoxathiazine-2,2-dione (7) 
The title compound was prepared according to General Procedure 
B from imine 6 (75 mg, 0.30 mmol) and allyltrifluoroborate 2c 
and was purified by column chromatography (10% 
EtOAc/hexane) to give a yellow solid (75 mg, 85%). 
Rf = 0.30 (10% EtOAc/hexane).  
m.p. 76-77°C (CH2Cl2/hexane).  
IR (neat): 3285 (NH), 1614, 1489, 1454, 1435, 1377, 1260, 1180, 
856, 762 cm-1.  
1H NMR (500 MHz, CDCl3): δ = 7.53 (d, J = 8.0 Hz, 1 H), 7.48 
(dt, J = 7.5, 5.4 Hz, 1 H), 7.34 (td, J = 8.0, 1.2 Hz, 1 H), 7.16 (dd, 
J = 8.2, 1.1 Hz, 1 H), 5.61-5.53 (m, 1 H), 5.41-5.36 (m, 2 H), 5.13 
(s, 1 H), 3.05 (dd, J = 14.5, 6.5 Hz, 1 H), 2.85 (dd, J = 14.5, 8.0 
Hz, 1 H). 
13C NMR (125.8 MHz, CDCl3): δ = 150.8, 131.5, 128.4, 127.0 (q, 
J = 2.6 Hz), 126.5, 124.3 (q, J = 286.3 Hz), 124.2, 120.0, 117.9, 
65.8 (q, J = 29.1 Hz), 41.3.  
19F NMR (376 MHz, CDCl3): δ = ‒74.7. 
HRMS (ESI): Exact mass calcd for C11H11F3NO3S [M+H]
+: 
294.0406, found: 294.0408.  
To facilitate determination of enantiomeric excess, 7 was 
converted into the primary alcohol 7a resulting from a 
hydroboration–oxidation sequence of the terminal alkene, 
according to the following procedure: 
 
4-(Trifluoromethyl)-3,4-dihydro-[1,2,3]-benzoxathiazine-2,2-
dione (7a) 
To a solution of the alkene 7 (66 mg, 0.23 mmol) in THF (3 mL) 
at 0 °C was added 9-BBN (0.5 M in THF, 1.37 mL, 0.68 mmol) 
over 2 min. The mixture was warmed to room temperature over 1 
h and then stirred for a further 23 h. The reaction was cooled to 0 
°C and 3 M NaOH (1 mL) and H2O2 (30 wt.% in H2O, 2 mL) were 
added successively. The resulting mixture was stirred for 1 h at 
room temperature, diluted with H2O (20 mL), acidified with 2 M 
HCl, and extracted with EtOAc (3 x 20 mL). The combined 
organic extracts were dried (MgSO4), filtered, and concentrated in 
vacuo. Purification of the residue by column chromatography 
(60% EtOAc/hexane) gave the alcohol 7a (61 mg, 86%) as a 
colorless gum.  
Rf = 0.41 (60% EtOAc/hexane). 
IR (neat): 3288 (OH and NH), 2924, 1454, 1375, 1177, 1159, 
1115, 1055, 856, 762 cm-1. 
1H NMR (CD3OD, 500 MHz): δ = 7.61 (d, J = 8.0 Hz, 1 H), 7.55-
7.52 (m, 1 H), 7.41-7.38 (m, 1 H), 7.19 (dd, J = 8.2, 1.2 Hz, 1 H), 
3.60-3.52 (m, 2 H), 2.45-2.39 (m, 1 H), 2.14-2.08 (m, 1 H), 1.76-
1.68 (m, 1 H), 1.38-1.26 (m, 1 H).  
13C NMR (125.8 MHz, CD3OD): δ = 152.9, 132.5, 125.0 (q, J = 
286.0 Hz), 127.4, 126.4 (q, J = 286.0 Hz), 120.7, 119.9, 68.1 (q, J 
= 28.6 Hz), 62.0, 33.1, 26.6. 
19F NMR (CD3OD): δ = –78.0. 
HRMS (ESI): Exact mass calcd for C11H12F3NO4SNa [M+Na]
+: 
334.0331, found: 334.0331.  
HPLC: Chiralpak AD-H column (90:10 hexane:i-PrOH, 0.8 
mL/min 280 nm, 25 °C); tr = 19.3 min, 29.0 min; 0% ee. 
(S)-3-Methyl-3-[(S)-1-hex-1-en-3-yl]-2,3-dihydro-[1,2]-
benzothiazole-1,1-dioxide (8a) 
The title compound was prepared according to General Procedure 
B from imine 4a (54 mg, 0.30 mmol) and allyltrifluoroborate 2d 
(86 mg, 0.45 mmol) and was purified by column chromatography 
(10% EtOAc/hexane) to give a yellow oil (38 mg, 48%).  
Rf = 0.38 (30% EtOAc/hexane).  
[α] 20
D
 ‒23.3 (c 0.60, CHCl3).  
IR (neat): 3219 (NH), 1389, 1377, 1271, 1238, 1153, 1134, 918, 
770, 719 cm-1.  
1H NMR (500 MHz, CDCl3): δ = 7.75 (d, J = 7.8 Hz, 1 H), 7.62 
(td, J = 7.8, 1.1 Hz, 1 H), 7.52 (td, J = 7.7, 0.9 Hz, 1 H), 7.37 (d, J 
= 7.9 Hz, 1 H), 5.59 (app dt, J = 17.0, 10.1 Hz, 1 H), 5.09 (dd, J = 
10.3, 1.8 Hz, 1 H), 4.99 (dd, J = 17.1, 1.7 Hz, 1 H), 4.61 (s, 1 H), 
2.43-2.37 (m, 1 H), 1.70-1.64 (m, 1 H), 1.63 (s, 3 H), 1.46-1.35 
(m, 1 H), 1.30-1.21 (m, 1 H), 1.20-1.10 (m, 1 H), 0.88 (t, J = 7.3 
Hz, 3 H).  
13C NMR (125.8 MHz, CDCl3): δ = 143.6, 136.8, 134.8, 132.9, 
129.2, 124.0, 121.4, 119.8, 65.9, 53.7, 30.8, 26.0, 20.6, 13.9.  
HRMS (ESI): Exact mass calcd for C14H20NO2S [M+H]
+: 
266.1209, found: 266.1208.  
HPLC: Chiralcel OD-H column (90:10 hexane:i-PrOH, 0.8 
mL/min, 211 nm, 25 °C); tr (major) = 11.6 min, tr (minor) = 18.6 
min; 98% ee.  
 
(S)-3-Methyl-3-[(R)-1-phenylprop-2-en-1-yl]-2,3-dihydro-[1,2]-
benzothiazole-1,1-dione (8b) 
The title compound was prepared according to General Procedure 
B from imine 4a (54 mg, 0.30 mmol) and allyltrifluoroborate 2e 
(100 mg, 0.45 mmol) and was purified by column chromatography 
(20% EtOAc/hexane) to give a gum that solidified on standing to 
give a white solid (77 mg, 86%).  
Rf = 0.26 (30% EtOAc/hexane). 
m.p. 78-79 °C (EtOAc/hexane). 
[α] 20
D
 ‒88.6 (c 3.70, CHCl3). 
IR (neat): 3233 (NH), 1389, 1373, 1275, 1153, 1132, 930, 891, 
756, 708 cm-1.  
1H NMR (500 MHz, CDCl3): δ = 7.77 (d, J = 7.7 Hz, 1 H), 7.60 
(td, J = 7.6, 1.3 Hz, 1 H), 7.53 (td, J = 7.5, 1.0 Hz, 1 H), 7.39-7.27 
(m, 5 H), 7.17 (d, J = 7.8 Hz, 1 H), 6.17 (ddd, J = 17.0, 10.2, 9.1 
Hz, 1 H), 5.03 (dd, J = 10.2, 1.2 Hz, 1 H), 4.95 (ddd, J = 17.0, 1.4, 
1.0 Hz, 1 H), 4.52 (s, 1 H), 3.69 (d, J = 9.0 Hz, 1 H), 1.51 (s, 3 H). 
13C NMR (125.8 MHz, CDCl3): δ = 143.0, 139.1, 135.9, 135.0, 
133.0, 129.3, 129.3 (2 × CH), 128.6 (2 × CH), 127.6, 123.8, 121.4, 
119.2, 66.0, 59.6, 27.1. 
HRMS (ESI): Exact mass calcd for C17H18NO2S [M+H]
+: 
300.1053, found: 300.1051. 
HPLC: Chiralcel OD-H column (90:10 hexane:i-PrOH, 0.8 
mL/min, 230 nm, 25 °C); tr (major) = 22.4 min, tr (minor) = 32.8 
min; 91% ee.  
 
(S)-3-Methyl-3-(2-methylprop-2-en-1-yl)-2,3-dihydro-[1,2]-
benzothiazole-1,1-dione (8c) 
The title compound was prepared according to General Procedure 
B from imine 4a (54 mg, 0.30 mmol) and allyltrifluoroborate 2f 
(73 mg, 0.45 mmol) and was purified by column chromatography 
(10% EtOAc/hexane) to give a yellow gum (40 mg, 56%).  
Rf = 0.31 (30% EtOAc/hexane). 
[α] 20
D
 ‒61.8 (c 0.55, CHCl3).  
IR (neat): 3273 (NH), 1369, 1277, 1263, 1163, 1150, 1128, 1057, 
893, 758 cm-1.  
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1H NMR (500 MHz, CDCl3): δ = 7.74 (t, J = 14.1 Hz, 1 H), 7.64 
(td, J = 7.7, 0.9 Hz, 1 H), 7.53 (td, J = 7.6, 0.6 Hz, 1 H), 7.43 (d, J 
= 7.8 Hz, 1 H), 5.02-5.01 (m, 1 H), 4.84 (s, 1 H), 4.75 (s, 1 H), 
2.74 (d, J = 13.9 Hz, 1 H), 2.59 (d, J = 13.9 Hz, 1 H), 1.65 (s, 3 
H), 1.57 (s, 3 H).  
13C NMR (125.8 MHz, CDCl3): δ = 145.4, 140.6, 135.4, 133.1, 
129.2, 123.2, 121.4, 117.8 , 62.5, 48.9, 29.0, 23.9.  
HRMS (ESI): Exact mass calcd for C12H16NO2S [M+H]
+: 
238.0896, found: 238.0893.  
HPLC: Chiralpak AD-H column (90:10 hexane:i-PrOH, 0.8 
mL/min, 211 nm, 25 °C); tr (major) = 20.6 min, tr (minor) = 25.6 
min; 98% ee. 
 
(S)-3-Methyl-3-[(S)-but-3-en-1-yl)-2,3-dihydro-[1,2]-
benzothiazole-1,1-dione (8d) and (S)-3-methyl-3-[(R)-but-3-en-
1-yl)-2,3-dihydro-[1,2]-benzothiazole-1,1-dione (11) 
General Procedure B was followed using imine 4a (54 mg, 0.30 
mmol) and allyltrifluoroborate 2g (73 mg, 0.45 mmol). 
Purification by column chromatography (10% EtOAc/hexane) 
gave the allylated product 8d as white solid (47 mg 66%) 
followed by allylated product 11 as a white solid (17 mg 24%). 
Recrystallization of 8d and 11 from Et2O gave colorless crystals, 
which enabled the stereochemistry of 8d to be determined by X-
ray crystallography. 
Data for 8d:  
Rf = 0.33 (30% EtOAc/hexane).  
m.p. 72-74 °C (Et2O). 
[α] 20
D
‒67.8 (c 1.15, CHCl3). 
IR (neat): 3250 (NH), 1267, 1234, 1157, 1134, 1125, 891, 766, 
718, 586 cm-1. 
1H NMR (500 MHz, CDCl3): δ = 7.75 (d, J = 7.8, 1 H), 7.62 (td, J 
= 7.8, 1.1 Hz, 1 H), 7.52 (td, J = 7.8, 0.9 Hz, 1 H), 7.37 (d, J = 5.7 
Hz, 1 H), 5.71 (ddd, J = 16.6, 11.0, 7.9 Hz, 1 H), 5.08-5.02 (m, 2 
H), 4.64 (s, 1 H), 2.74-2.67 (m, 1 H), 1.63 (s, 3 H) 1.17 (d, J = 6.9 
Hz, 3 H).  
13C NMR (125.8 MHz, CDCl3): δ = 143.8, 138.1, 135.2, 133.0, 
129.2, 123.7, 121.4, 117.9, 65.9, 47.0, 26.0, 14.6.  
HRMS (ESI): Exact mass calcd for C12H16NO2S [M+H]
+: 
238.0896, found: 238.0898. 
HPLC: Chiralcel OD-H column (90:10 hexane:i-PrOH, 0.8 
mL/min, 211 nm, 25 °C); tr (major) = 15.0 min, tr (minor) = 22.5 
min; 98% ee.  
Data for 11:  
Rf = 0.29 (30% EtOAc/hexane).  
m.p. 134-136 °C (Et2O).  
[α] 20
D
‒65.2 (c 0.50, CHCl3). 
IR (neat): 3283 (NH), 1366, 1273, 1234, 1177, 1152, 1134, 934, 
764, 590 cm-1. 
1H NMR (500 MHz, CDCl3): δ = 7.77 (d, J = 7.8 Hz, 1 H), 7.66 
(td, J = 7.8, 1.1 Hz, 1 H), 7.55 (td, J = 7.8, 0.9 Hz, 1 H), 7.37 (d, J 
= 7.9 Hz, 1 H), 5.85 (ddd, J = 17.1, 10.3, 8.4 Hz, 1 H), 5.24 (dd, J 
= 10.3, 1.0 Hz, 1 H), 5.22-5.17 (m, 1 H), 4.33 (s, 1 H), 2.67-2.61 
(m, 1 H), 1.62 (s, 3 H), 0.87 (d, J = 6.8 Hz, 3 H). 
13C NMR (125.8 MHz, CDCl3): δ = 143.7, 138.2, 135.2, 133.3, 
129.3, 123.2, 121.5, 118.1, 66.0, 47.3, 27.7, 15.0.  
HRMS (ESI): Exact mass calcd for C12H16NO2S [M+H]
+: 
238.0896, found: 238.0897. 
HPLC: Chiralcel OD-H column (90:10 hexane:i-PrOH, 0.8 
mL/min, 211 nm, 25 °C); tr (major) = 13.6 min, tr (minor) = 22.2 
min; 98% ee.  
 
(S)-4-[(R)-1-phenylprop-2-en-1-yl]-3,4-dihydro-[1,2,3]-
benzoxathiazine-2,2-dioxide (13a) 
The title compound was prepared according to General Procedure 
C from imine 1 (55 mg, 0.30 mmol) and allyltrifluoroborate 2e 
(101 mg, 0.45 mmol) and was purified by column chromatography 
(10% EtOAc/hexane) to give a yellow oil (81 mg, 90%).  
Rf = 0.50 (30% EtOAc/hexane).  
[α] 20
D
‒85.0 (c 0.80, CHCl3). 
IR (neat): 3273 (NH), 1414, 1364, 1321, 1165, 1103, 874, 822, 
756, 696 cm-1. 
1H NMR (500 MHz, CDCl3): δ = 7.42-7.37 (m, 2 H), 7.35-7.31 
(m, 4 H), 7.12 (td, J = 7.5, 1.2 Hz, 1 H), 7.08-7.05 (m, 2 H), 6.04 
(ddd, J = 17.4, 10.4, 7.2 Hz, 1 H), 5.34 (dt, J = 10.4, 1.3 Hz, 1 H), 
5.16-5.12 (m, 1 H), 5.11 (dt, J = 17.3, 1.3 Hz, 1 H), 4.75 (d, J = 
7.4 Hz, 1 H) 4.24 (dd, J = 13.3, 6.6 Hz, 1 H).  
13C NMR (125.8 MHz, CDCl3): δ = 151.5, 138.6, 134.8, 129.7, 
129.0 (2 × CH), 128.6 (2 × CH), 127.7, 126.9, 125.3, 121.5, 121.1, 
119.2, 60.2, 52.5.  
HRMS (ESI): Exact mass calcd for C16H16NO3S [M+H]
+: 
302.0845, found: 302.0846.  
HPLC: Chiralpak AD-H column (90:10 hexane:i-PrOH, 0.8 
mL/min, 211  nm, 25 °C); tr (major) = 13.8 min, tr (minor) = 15.8 
min; 95% ee. 
 
(S)-4-(2-Methylprop-2-en-1-yl)-3,4-dihydro-[1,2,3]-
benzoxathiazine-2,2-dioxide (13b) 
The title compound was prepared according to General Procedure 
C from imine 1 (55 mg, 0.30 mmol) and allyltrifluoroborate 2f (73 
mg, 0.45 mmol) and was purified by column chromatography 
(10% EtOAc/hexane) to give a colorless oil (47 mg 65%).  
Rf = 0.56 (30% EtOAc/hexane). 
[α] 20
D
‒45.2 (c 0.85, CHCl3). 
IR (neat): 3273 (NH), 1406, 1360, 1188, 1165, 1103, 891, 816, 
758, 675 cm-1. 
1H NMR (500 MHz, CDCl3): δ = 7.35-7.30 (m, 1 H), 7.28-7.26 
(m, 1 H), 7.24-7.20 (m, 1 H), 7.04 (dd, J = 8.2, 1.1 Hz, 1 H), 5.01 
(d, J = 0.5 Hz, 1 H), 4.96 (app td, J = 8.6, 4.7 Hz, 1 H), 4.91 (s, 1 
H), 4.63 (d, J = 7.8 Hz, 1 H), 2.88 (dd, J = 14.5, 4.7 Hz, 1 H), 2.69 
(ddd, J = 14.5, 9.2, 0.7 Hz, 1 H), 1.76 (s, 3 H). 
13C NMR (125.8 MHz, CDCl3): δ = 151.0, 139.9, 129.5, 126.3, 
125.4, 122.4, 119.1, 116.2, 54.4, 42.6, 22.0.  
HRMS (ESI): Exact mass calcd for C11H13NO3S [M+Na]+: 
262.0508, found: 262.0509.  
HPLC: Chiralpak AD-H column (95:5 hexane:i-PrOH, 0.8 
mL/min, 280 nm, 25 °C); tr (major) = 20.2 min, tr (minor) = 23.3 
min; 79% ee.  
 
(S)-4-[(R)-Cyclohex-2-en-1-yl]-3,4-dihydro-[1,2,3]-
benzoxathiazine-2,2-dioxide (13c) 
The title compound was prepared according to General Procedure 
B from imine 1 (55 mg, 0.30 mmol) and allyltrifluoroborate 2h 
(85 mg, 0.45 mmol) and was purified by column chromatography 
(10% EtOAc/hexane) to give a 10:1 inseparable mixture of 
diastereomers as a white solid (29 mg, 36%). Recrystallization of 
a small sample of 13c from Et2O gave colorless crystals that were 
suitable for X-ray crystallography.  
Rf = 0.54 (30% EtOAc/hexane). 
m.p. 128-130 °C (Et2O). 
[α] 20
D
‒38.4 (c 1.25, CHCl3). 
IR (neat): 3273 (NH), 1408, 1369, 1184, 1171, 1161, 878, 826, 
766, 719 cm-1. 
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1H NMR (500 MHz, CDCl3): δ = 7.35-7.31 (m, 1 H), 7.25-7.22 
(m, 2 H), 7.06-7.04 (m, 1 H), 6.04-5.99 (m, 1 H), 5.62-5.58 (m, 1 
H), 4.90 (dd, J = 6.4, 5.0 Hz, 1 H), 4.54 (d, J = 6.2 Hz, 1 H), 3.13-
3.06 (m, 1 H), 2.08-2.00 (m, 2 H), 1.82-1.75 (m, 1 H), 1.59-1.49 
(m, 2 H), 1.27-1.18 (m, 1 H).  
13C NMR (125.8 MHz, CDCl3): δ = 151.6, 132.3, 129.3, 126.6, 
126.3, 125.5, 121.4, 119.2, 60.1, 39.0, 24.9, 22.2, 21.4.  
HRMS (ESI): Exact mass calcd for C13H16NO3S [M+H]
+: 
266.0845, found: 266.0846. 
HPLC: Chiralcel OD-H column (95:5 hexane:i-PrOH, 0.8 
mL/min, 254 nm, 25 °C); tr (major) = 14.2 min, tr (minor) = 24.2 
min; 93% ee.  
 
(S)-(2-Methylbut-3-en-2-yl)-3,4-dihydro-[1,2,3]-
benzoxathiazine-2,2-dioxide (13d)8 
The title compound was prepared according to General Procedure 
C from imine 1 (55 mg, 0.30 mmol) and allyltrifluoroborate 2i (79 
mg, 0.45 mmol) and was purified by column chromatography 
(20% EtOAc/hexane) to give a yellow oil (54 mg, 71%) that 
displayed spectroscopic data consistent with those reported 
previously.8  
Rf = 0.54 (30% EtOAc/hexane). 
[α] 20
D
‒60.0 (c 0.50, CHCl3). 
HPLC: Chiralpak AD-H column (95:5 hexane:i-PrOH, 0.8 
mL/min, 211 nm, 25 °C); tr (major) = 13.9 min, tr (minor) = 25.1 
min; 90% ee.  
 
(S)-3-Methyl-4-phenyl-3[(R)-1-phenylprop-2-en-1-yl]-2,3-
dihydro-[1,2,5]-thiadiazole-1,1-dioxide (13e) 
The title compound was prepared according to General Procedure 
B from imine 12 (62 mg, 0.30 mmol) and allyltrifluoroborate 2e 
(101 mg, 0.45 mmol) and was purified by column chromatography 
(10% EtOAc/hexane) to give a colorless gum (84 mg, 86%).  
Rf = 0.26 (30% EtOAc/hexane). 
[α] 20
D
+52.7 (c 2.20, CHCl3). 
IR (neat): 3242 (NH), 1558, 1315, 1175, 1146, 995, 820, 710, 689, 
652 cm-1. 
1H NMR (500 MHz, CDCl3): δ = 8.12-8.08 (m, 2 H), 7.70-7.65 
(m, 1 H), 7.59-7.54 (m, 2 H), 7.42-7.38 (m, 4 H), 7.35-7.31 (m, 1 
H), 6.24 (ddd, J = 17.0, 10.1, 9.4 Hz, 1 H), 5.03 (dd, J = 10.2, 1.2 
Hz, 1 H), 4.97 (d, J = 17.0 Hz, 1 H), 4.48 (s, 1 H), 3.88 (d, J = 9.3 
Hz, 1 H), 1.67 (s, 3 H).  
13C NMR (125.8 MHz, CDCl3): δ = 181.0, 138.1, 134.4, 133.7, 
130.2 (2 × CH), 129.4 (2 × CH), 129.3, 129.1 (2 × CH), 128.9 (2 × 
CH), 128.0, 119.5, 75.9, 57.2, 26.1.  
HRMS (ESI): Exact mass calcd for C18H19N2O2S [M+H]
+: 
327.1162, found: 327.1160.  
HPLC: Chiralpak AD-H column (90:10 hexane:i-PrOH, 0.8 
mL/min, 254 nm, 25 °C); tr (major) = 23.9 min, tr (minor) 25.2 
min; 95% ee.  
  
(S)-3-Methyl-3-(2-methylprop-2-en-1-yl)-4-phenyl-2,3-
dihydro-[1,2,5]-thiadiazole-1,1-dioxide (13f) 
The title compound was prepared according to General Procedure 
B from imine 12 (62 mg, 0.30 mmol) and allyltrifluoroborate (73 
mg, 0.45 mmol) and was purified by column chromatography 
(10% EtOAc/hexane) to give a yellow oil (71 mg, 90%).  
Rf = 0.26 (30% EtOAc/hexane). 
[α] 20
D
‒25.0 (c 0.80, CHCl3). 
IR (neat): 3300 (NH), 1553, 1294, 1175, 1144, 907, 824, 783, 692, 
654 cm-1. 
1H NMR (500 MHz, CDCl3): δ = 8.07 (dd, J = 8.5, 1.2 Hz, 2 H), 
7.67-7.62 (m, 1 H), 7.57-7.52 (m, 2 H), 5.08-5.04 (m, 1 H), 4.87 
(s, 1 H), 4.74 (s, 1 H), 2.98 (d, J = 14.5 Hz, 1 H), 2.73 (dd, J = 
14.5, 0.6 Hz, 1 H), 1.84 (s, 3 H), 1.67 (s, 3 H).  
13C NMR (125.8 MHz, CDCl3): δ = 182.3, 139.5, 133.8 , 130.2 (2 
× CH), 129.2 (2 × CH), 128.9, 118.6, 71.6, 46.7, 27.5, 23.4.  
HRMS (ESI): Exact mass calcd for C13H17N2O2S [M+H]
+: 
265.1005, found: 265.1000. 
HPLC: Chiralcel OD-H column (90:10 hexane:i-PrOH, 0.8 
mL/min, 254 nm, 25 °C); tr (major) = 16.1 min, tr (minor) = 19.2 
min; 97% ee. 
 
(S)-3-Methyl-3-(2-methylbut-3-en-2-yl)-4-phenyl-2,3-dihydro-
[1,2,5]-thiadiazole-1,1-dioxide (13 H)8 
The title compound was prepared according to General Procedure 
B from imine 12 (62 mg, 0.30 mmol) and allyltrifluoroborate 2i 
(79 mg, 0.45 mmol) and was purified by column chromatography 
(10% EtOAc/hexane) to give a yellow solid (72 mg, 87%) that 
displayed spectroscopic data consistent with those reported 
previously.8  
Rf = 0.25 (30% EtOAc/hexane).  
[α] 20
D
+40.7 (c 1.40, CHCl3).  
HPLC: Chiralpak AD-H column (90:10 hexane:i-PrOH, 0.8 
mL/min, 211 nm, 25 °C); tr (major) = 22.1 min, tr (minor) = 29.2 
min; 91% ee. 
 
(S)-4-[(S)-But-3-en-2-yl]-3,4-dihydro-[1,2,3]-benzoxathiazine-
2,2-dioxide (ent-3a)8 and (S)-4-[(R)-but-3-en-2-yl]-3,4-dihydro-
[1,2,3]-benzoxathiazine-2,2-dioxide (ent-3b)8 
General Procedure B was followed using imine 1 (55 mg, 0.30 
mmol) and allyltrifluoroborate 2g (73 mg, 0.45 mmol). 
Purification by column chromatography (20% EtOAc/hexane) 
gave a 2:1 inseparable mixture of the allylated products ent-3a and 
ent-3b as a yellow oil (43 mg, 60%) that displayed spectroscopic 
data consistent with those reported previously.8  
Rf = 0.52 (30% EtOAc/hexane). 
Data for ent-3a:  
HPLC: Chiralpak AD-H column (98:2 hexane:i-PrOH, 0.8 
mL/min, 225 nm, 25 °C); tr (major) = 18.5 min, tr (minor) = 38.6 
min; 93% ee.  
Data for ent-3b:  
HPLC: Chiralpak AD-H column (98:2 hexane:i-PrOH, 0.8 
mL/min, 225 nm, 25 °C); tr (major) = 21.7 min, tr (minor) = 43.0 
min; 97% ee.  
 
3(S)-3-[(S)-But-3-en-2-yl]-3-methyl-4-phenyl-2,3-dihydro-
[1,2,5]-thiadiazole 1,1-dioxide (13i)8 and 3(S)-3-[(R)-but-3-en-
2-yl]-3-methyl-4-phenyl-2,3-dihydro-[1,2,5]-thiadiazole-1,1-
dioxide (13j)8 
General Procedure B was followed using imine 12 (62 mg, 0.30 
mmol) and allyltrifluoroborate 2g (73 mg, 0.45 mmol). 
Purification by column chromatography (10% EtOAc/hexane) 
gave the allylated product 13j as a yellow oil (13 mg, 16%) 
followed by the allylated product 13i as a yellow oil (38 mg, 48%) 
that displayed spectroscopic data consistent with those reported 
previously.8 Both 13i and 13j were contaminated with small 
quantities (<10%) of each other. 
Data for 13i:  
Rf = 0.22 (30% EtOAc/hexane). 
[α] 20
D
+23.0 (c 1.00, CHCl3).  
HPLC: Chiralcel OD-H column (90:10 hexane:i-PrOH, 0.8 
mL/min, 254 nm, 25 °C); tr (major) = 13.0 min, tr (minor) = 22.2 
min; 97% ee. 
Data for 13j: 
Rf = 0.30 (30% EtOAc/hexane). 
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[α] 20
D
+16.6 (c 0.30, CHCl3).  
HPLC: Chiralcel OD-H column (90:10 hexane:i-PrOH, 0.8 
mL/min, 254 nm, 25 °C); tr (major) = 11.0 min, tr (minor) = 17.3 
min; 91% ee.  
 
tert-Butyl N-[(R)-1-(2-hydroxyphenyl)but-3-en-1-yl]carbamate 
(17) 
To a solution of allylation product 168 in THF (1 mL) at room 
temperature was added LiAlH4 (1.0 M in THF, 0.37 mL, 0.37 
mmol) over 1 min at room temperature. The mixture was heated at 
60 °C for 15 h, allowed to cool to temperature, and then cooled 
with an ice bath. The reaction was quenched carefully with EtOAc 
(1 mL), followed by the addition of EtOH (1 mL) and H2O (2 
mL). To the resulting turbid mixture was added Boc2O (81 mg, 
0.37 mmol) in one portion and the resulting mixture was stirred at 
room temperature for 1 h. The reaction was diluted with EtOAc 
(20 mL) and acidified with 2 M HCl until the aqueous layer 
became clear. The aqueous layer was separated and extracted with 
EtOAc (2 × 20 mL). The combined organic layers were dried 
(MgSO4), filtered, and concentrated in vacuo. Purification of the 
residue by column chromatography (6:1 hexane:Et2O→2:1 
hexane:Et2O) gave the carbamate 17 as a colorless oil (28 mg, 
85%).  
Rf = 0.54 (30% EtOAc/hexane). 
[α] 20
D
+45.2 (c 1.15, CHCl3). 
IR (neat): 3310 (OH), 2925, 1680, 1502, 1456, 1367, 1170, 1043, 
918, 860, 750 cm-1. 
1H NMR (500 MHz, CDCl3): δ = 8.50 (br s, 1 H), 7.16-7.07 (m, 2 
H), 6.88-6.80 (m, 2 H), 5.75 (ddt, J = 17.1, 10.2, 6.9 Hz, 1 H), 
5.27 (br s, 1 H), 5.13 (dd, J = 17.2, 1.0 Hz, 1 H), 5.09 (d, J = 10.4 
Hz, 1 H), 4.89 (br s, 1 H), 2.62 (t, J = 7.0 Hz, 2 H), 1.47 (s, 9H).  
13C NMR (125.8 MHz, CDCl3): δ = 157.0, 154.7, 134.6, 128.5, 
127.9, 126.6, 119.8, 117.8, 117.0, 80.7, 48.9, 38.6, 28.4 (3 × CH3).  
HRMS (EI): Exact mass calcd for C15H22O3N [M+H]
+: 264.1594, 
found: 264.1599. 
HPLC: Chiralpak AS-H column (98:2 hexane:i-PrOH, 0.8 
mL/min, 230 nm, 25 °C); tr (major) = 23.1 min, tr (minor) = 30.6 
min; 93% ee.  
 
(S)-4-(3-Hydroxypropyl)-3,4-dihydro-[1,2,3]-benzoxathiazine-
2,2-dioxide (18) 
To a solution of the alkene 16 (prepared as described previously8 
by the reaction of imine 1 with potassium allyltrifluoroborate, but 
using chiral diene ent-L1) (225 mg, 1.00 mmol) in THF (3 mL) at 
0 °C was added 9-BBN (0.5 M in THF, 6.0 mL, 3.0 mmol) over 2 
min. The mixture was warmed to room temperature over 1 h and 
then stirred for a further 23 h. The reaction was cooled to 0 °C and 
3 M NaOH (3 mL) and H2O2 (30 wt.% in H2O, 6 mL) were added 
successively. The resulting mixture was stirred for 1 h at room 
temperature, diluted with H2O (20 mL), acidified with 2 M HCl, 
and extracted with EtOAc (3 × 40 mL). The combined organic 
extracts were dried (MgSO4), filtered, and concentrated in vacuo. 
Purification of the residue by column chromatography (80% 
EtOAc/hexane) gave the alcohol 18 as a white solid (182 mg, 
75%).  
m.p. 112-113°C (CH2Cl2).  
Rf = 0.36 (80% EtOAc/hexane).   
[α] 20
D
‒36.7 (c 0.49, CHCl3).  
IR (neat): 3255 (OH), 2880, 1485, 1452, 1425, 1371, 1175, 1107, 
883, 760 cm-1.  
1H NMR (500 MHz, CD3OD): δ = 7.40 (d, J = 7.8 Hz, 1 H), 7.36 
(ddd, J = 8.3, 4.5, 1.1 Hz, 1 H), 7.24 (td, J = 1.6, 1.2 Hz, 1 H), 
7.02 (dd, J = 8.2, 1.2 Hz, 1 H), 4.70 (dd, J = 10.9, 3.8 Hz, 1 H), 
3.70-3.61 (m, 2 H), 2.26-2.18 (m, 1 H), 2.03-1.95 (m, 1 H), 1.90-
1.82 (m, 1 H), 1.76-1.67 (m, 1 H). 
13C NMR (125.8 MHz, CD3OD): δ = 152.8, 130.2, 127.9, 126.1, 
125.0, 119.3, 62.3, 57.9, 31.3, 29.6.  
HRMS (ESI): Exact mass calcd for C10H14NO4S [M+H]
+: 
244.0638, found: 244.0640.  
 
(S)-8-Oxa-7λ6-thia-6-azatricyclo[7.4.0.02,6]trideca-1(9),10,12-
triene-7,7-dioxide (19) 
To a solution of the alcohol 18 (61 mg, 0.25 mmol) and PPh3 (85 
mg, 0.33 mmol) in CH2Cl2 (4 mL) at 0 °C was added a solution of 
DEAD (53 mg, 0.30 mmol) in CH2Cl2 (1 mL). The mixture was 
allowed to warm to room temperature over 1 h and then stirred for 
an additional 9 h. The reaction was quenched with EtOH (1 mL) 
and concentrated in vacuo. Purification of the residue by column 
chromatography (60% EtOAc/hexane) gave the product (56 mg, 
>95%) as a white solid.  
m.p. 85-86 °C (EtOAc/hexane).  
Rf = 0.57 (60% EtOAc/hexane). 
[α] 20
D
‒125.0 (c 0.40, CHCl3). 
IR (neat): 2982, 1485, 1450, 1392, 1206, 1175, 1103, 1005, 856, 
758 cm-1. 
1H NMR (500 MHz, CDCl3): δ = 7.30 (dddd, J = 8.1, 7.3, 1.7, 0.8 
Hz, 1 H), 7.21 (td, J = 7.5, 1.2 Hz, 1 H), 7.15 (dt, J = 7.5, 1.0 Hz, 
1 H), 7.01 (dd, J = 8.2, 1.2 Hz, 1 H), 5.20 (dd, J = 7.4, 2.5 Hz, 1 
H), 3.61-3.56 (m, 1 H), 3.51 (ddd, J = 10.1, 8.6, 5.8 Hz, 1 H), 2.59 
(ddd, J = 16.5, 12.8, 7.7 Hz, 1 H), 2.30-2.24 (m, 1 H), 2.07-1.99 
(m, 1 H), 1.92-1.83 (m, 1 H). 
13C NMR (125.8 MHz, CDCl3): δ = 151.0, 129.1, 126.6, 125.6, 
122.5, 118.8, 62.7, 49.7, 34.0, 23.4.  
HRMS (EI): Exact mass calcd for C10H12NO3S [M+H]
+: 226.0532, 
found: 226.0529. 
HPLC: Chiralpak AD-H column (95:5 hexane:i-PrOH, 0.8 
mL/min, 280 nm, 25 °C); tr (minor) = 18.6 min, tr (major) = 20.2 
min; 92% ee. 
 
tert-Butyl-N-[(S)-4-hydroxy-1-(2-hydroxyphenyl)butyl] 
carbamate (20) 
To a solution of the cyclic sulfamate 18 (100 mg, 0.41 mmol) in 
THF (2 mL) at room temperature was added LiAlH4 (2.0 M in 
THF, 0.62 mL, 1.24 mmol) dropwise over 4 min. The mixture was 
heated at 60 °C for 2 h, allowed to cool to room temperature, and 
then cooled with an ice bath. The reaction was quenched carefully 
with EtOAc (2 mL), followed by the addition of EtOH (2 mL) and 
H2O (2 mL). To the resulting turbid mixture was added Boc2O 
(268 mg, 1.24 mmol) in one portion and the resulting mixture was 
stirred at room temperature for 1 h. The reaction was diluted with 
EtOAc (40 mL) and acidified with 2 M HCl until the aqueous 
layer became clear. The aqueous layer was separated and extracted 
with EtOAc (2 × 40 mL). The combined organic layers were dried 
(MgSO4), filtered, and concentrated in vacuo. Purification of the 
residue by column chromatography (80% EtOAc/hexane) gave the 
carbamate 20 (87 mg, 75%) as a colorless gum.  
Rf = 0.42 (80% EtOAc/hexane). 
[α] 20
D
‒33.6 (c 0.24, CHCl3). 
IR (neat): 3305 (OH and NH), 2980, 1680 (C=O), 1502, 1456, 
1367, 1292, 1253, 1165, 752, 742 cm-1. 
1H NMR (500 MHz, CDCl3): δ = 8.28 (br s, 1 H), 7.18 (dd, J = 
12.1, 4.5 Hz, 2 H), 6.93 (d, J = 7.8 Hz, 1 H), 6.90 (dt, J = 7.5, 1.1 
Hz, 1 H), 5.13 (s, 1 H), 4.86 (d, J = 6.9 Hz, 1 H), 3.72 (dt, J = 6.2, 
0.9 Hz, 2 H), 2.06-1.95 (m, 2 H), 1.73-1.58 (m, 2 H), 1.45 (s, 9H). 
13C NMR (125.8 MHz, CDCl3): δ = 157.3, 154.9, 128.8, 128.4, 
126.3, 120.3, 117.8, 80.8, 62.3, 49.0, 30.6, 29.5, 28.3 (3 × CH3). 
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HRMS (ESI): Exact mass calcd for C15H24NO4 [M+H]
+: 282.1700, 
found: 282.1696. 
 
tert-Butyl N-[(S)-2,3,4,5-tetrahydro-1-benzoxepin-5-yl] 
carbamate (21) 
To a solution of the alcohol 20 (68 mg, 0.24 mmol) and PPh3 (82 
mg, 0.31 mmol) in CH2Cl2 (4 mL) at 0 °C was added a solution of 
DEAD (51 mg, 0.29 mmol) in CH2Cl2 (1 mL). The mixture was 
allowed to warm to room temperature over 1 h and then stirred for 
an additional 9 h. The reaction was quenched with EtOH (1 mL) 
and concentrated in vacuo. Purification of the residue by column 
chromatography (20% EtOAc/hexane) gave the 
tetrahydrobenzoxepine 21 as a white solid (43 mg, 68%).  
m.p. 105-106°C (CH2Cl2/hexane). 
Rf = 0.40 (20% EtOAc/hexane). 
[α] 20
D
‒40.0 (c 0.15, CHCl3). 
IR (neat): 3300 (NH), 2976, 2930, 1713 (C=O), 1450, 1366, 1236, 
1224, 1170, 760 cm-1.  
1H NMR (500 MHz, CDCl3): δ = 7.28-7.26 (m, 1 H), 7.20 (td, J = 
7.7, 1.7 Hz, 1 H), 7.05 (td, J = 7.5, 1.3 Hz, 1 H), 7.01 (dd, J = 7.5, 
1.3 Hz, 1 H), 5.29 (d, J = 7.8 Hz, 1 H), 4.91 (t, J = 7.1 Hz, 1 H), 
4.30 (app d, J = 11.9 Hz, 1 H), 3.75 (app t, J = 11.2 Hz, 1 H), 
2.30-2.10 (m, 2 H), 1.88-1.81 (m, 1 H), 1.79-1.72 (m, 1 H), 1.44 
(s, 9H). 
13C NMR (125.8 MHz, CDCl3): δ = 159.3, 155.0, 135.5, 129.3, 
128.9, 124.2, 122.0, 79.3, 73.8 , 53.9, 30.8, 28.4 (3 × CH3), 26.7.  
HRMS (ESI): Exact mass calcd for C15H22NO3 [M+H]
+: 264.1594, 
found: 264.1595. 
HPLC: Chiralpak AD-H column (98:2 hexane:i-PrOH, 0.8 
mL/min, 280 nm, 25 °C); tr (major) = 12.5 min, tr (minor) = 15.6 
min; 90% ee. 
 
(3S,4R)-3-Methyl-4-phenyl-3-(prop-2-en-1-yl)-[1,2,5]-
thiadiazolidine-1,1-dioxide (24) 
To a solution of the imine 23 (prepared as described previously8 
by the reaction of imine 12 with allyltrifluoroborate 2c, but using 
chiral diene ent-L1) (200 mg, 0.80 mmol) in THF (32 mL) at ‒20 
°C was added DIBAL (1.0 M in THF, 3.2 mL, 3.2 mmol) over 2 
min. The mixture was warmed gradually to room temperature over 
2 h and stirred for a further 13 h. The reaction was quenched 
carefully with 1 M HCl solution until the pH value of the mixture 
reached 3. The mixture was diluted with H2O (20 mL) and EtOAc 
(30 mL), and the organic layer was separated. The aqueous layer 
was extracted with EtOAc (2 × 30 mL), and the combined organic 
layers were washed with brine (30 mL), dried (MgSO4), filtered, 
and concentrated in vacuo. Purification of the residue by column 
chromatography (33% EtOAc/hexane) gave the cyclic sulfamide 
24 as a colorless amorphous solid (182 mg, 90%).  
Rf = 0.26 (30% EtOAc/hexane). 
[α] 20
D
‒75.8 (c 0.42, CH3OH). 
IR (neat): 3271 (NH), 2980, 1454, 1381, 1312, 1265, 1157, 922, 
741, 702 cm-1. 
1H NMR (500 MHz, CDCl3): δ = 7.43-7.36 (m, 5 H), 5.67 (dddd, 
J = 17.1, 10.2, 7.8, 7.0 Hz, 1 H), 5.21-5.19 (m, 1 H), 5.14 (ddd, J 
= 17.1, 3.0, 1.3 Hz, 1 H), 4.90 (d, J = 5.1 Hz, 1 H), 4.82 (d, J = 5.1 
Hz, 1 H), 4.60 (s, 1 H), 2.49 (dd, J = 13.7, 7.9 Hz, 1 H), 1.59 (dd, 
J = 13.7, 6.9 Hz, 1 H), 1.43 (s, 3 H). 
13C NMR (125.8 MHz, CDCl3): δ = 134.1, 131.9, 128.9, 128.8 (2 
× CH), 127.3 (2 × CH), 121.2, 70.0, 65.0, 39.7, 24.2.  
HRMS (EI): Exact mass calcd for C12H16N2O2S [M]
+: 252.0927, 
found: 252.0928. 
HPLC: Chiralcel OD-H column (80:20 hexane:i-PrOH, 0.8 
mL/min, 211 nm, 25 °C); tr (major) = 13.9 min, tr (minor) = 28.1 
min; 97% ee. 
(1R,2S)-2-Methyl-1-phenyl-4-butene-1,2-diamine (25) 
A solution of cyclic sulfamide 24 (101 mg, 0.40 mmol) and 
ethylenediamine (267 µL, 4.00 mmol) in dioxane (6 mL) was 
stirred at 100 °C for 15 h. The reaction was cooled to room 
temperature and concentrated in vacuo. To the residue was added 
a 1.25 M solution of HCl in MeOH (2 mL) and the resulting 
solution was stirred at room temperature for 2 h before being 
concentrated in vacuo. The residue was dissolved in H2O (10 mL) 
and washed with EtOAc (2 × 10 mL). The organic layers were 
discarded and the aqueous phase was basified with 3 M NaOH (2 
mL) and extracted with EtOAc (3 × 20 mL). The combined 
organic extracts were dried (MgSO4), filtered, and concentrated in 
vacuo to leave the diamine 25 (67 mg, 88%) as a pale yellow oil. 
Rf = 0.15 (EtOAc). 
[α] 20
D
‒30.0 (c 0.20, MeOH). 
IR (neat): 3400 (NH), 2964, 1638, 1603, 1492, 1452, 1373, 999, 
914, 704 cm-1. 
1H NMR (500 MHz, CDCl3): δ = 7.39-7.31 (m, 5 H), 5.89 (ddt, J 
= 17.5, 10.2, 7.4 Hz, 1 H), 5.12 (ddt, J = 10.2, 2.0, 0.9 Hz, 1 H), 
5.08 (ddt, J = 17.0, 2.3, 1.4 Hz, 1 H), 3.82 (s, 1 H), 2.13-2.03 (m, 
2 H), 1.65 (br s, 4 H), 1.09 (s, 3 H). 
13C NMR (125.8 MHz, CDCl3): δ = 142.6, 134.3, 128.3 (2 × CH), 
127.9 (2 × CH), 127.2, 118.3, 64.2, 54.7, 44.0, 24.7.  
HRMS (EI): Exact mass calcd for C12H18N2 [M]
+: 190.1465, 
found: 190.1465. 
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